MBX Biosciences (MBX) executive compensation, 2026 proxy

P. Kent Hawryluk, President and Chief Executive Officer, was paid $3M in 2025, up 34% from $2.2M the year before.

Filed
April 22, 2026
Annual meeting
June 4, 2026
Pay year
2025
Named executives
3
CEO total pay
$3M+34% vs prior year
CEO Salary
$625,000Fiscal 2025 base salary
CEO Option Awards
$1,998,092Grant date fair value
CEO Non-Equity Incentive
$359,375Annual cash bonus earned
Total NEO Compensation
$5,962,120Combined total for all listed NEOs

How Hawryluk was paid

$3M in total for 2025, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.

Salary21%Option awards67%Non-equity incentive12%All other compensation0%

Named executive officers

ExecutiveTotal
P. Kent HawrylukPresident and Chief Executive Officer$2,990,867
Richard BartramFormer Chief Financial Officer$1,496,275
Salomon Azoulay, M.D.Chief Medical Officer$1,474,978

What changed and why

  • $3MCEO total compensation increased to $2,990,867 in fiscal 2025.
  • Option awards represented the majority of executive compensation.
  • Annual bonuses were determined based on corporate performance milestones and individual goals.
  • The company began providing 401(k) matching contributions in 2025.
  • Former CFO Richard Bartram resigned effective March 15, 2026.

About this page

Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.